Tumor infiltrating lymphocytes (TILs) and TCRs can recognize only the antigens presented by specific MHC molecules and tumors may escape immune surveillance due to downregulation or mutation of MHC molecules in tumor cells, resulting in clinical limitations (47). This evidence concerns the gene HLA-C and neoplasm.